REG - Diaceutics PLC - Expansion of US Commercial Activities

DiaceuticsAnnouncement

28/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241128:nRSb9305Na&default-theme=true

RNS Number : 9305N  Diaceutics PLC  28 November 2024

Diaceutics - Expansion of US Commercial Activities

 

Belfast and London, 28 November 2024 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, is pleased to provide an update
to the scaling of its US commercial activities strategy. A commercial data
partnership agreement was executed in H1 2024, and a further four agreements
were executed in H2 2024 to date, with a total contract value in the first
year of £1.13 million ($1.48 million). The commercial data partnership
contracts already underway are contributing to revenue in 2024 and Annual
Recurring Revenue (ARR) growth.

 

Commercial data partnerships expand Diaceutics' US commercial reach through
marketplaces and leverage partner sales teams in a co-selling model. The
directors believe these contracts will further scale the company's commercial
reach through the selling of high-margin data products, such as DXRX Signal,
to a broader customer base, both in terms of new customer segments and
pharmaceutical brands.

 

Ryan Keeling, Chief Executive Officer of Diaceutics, commented: "We are really
excited by these new agreements and the ability to offer our DXRX platform to
a much wider audience and, in the process, grow and scale our market
opportunity. We are pleased to see these partnerships contributing revenue and
ARR ahead of plan in 2024".

 

Enquiries:

 

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUBSWRSBUAUAA